Press releases
Access archived Guidant press releases
Access archived BTG press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 7, 2010Patients experienced a 50 percent relative reduction in risk of death compared to in-clinic follow-up
Boston Scientific Corporation (NYSE: BSX) today welcomed the publication of an analysis from its ALTITUDE® Clinical Science program in the current issue of
-
Nov 22, 2010
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Piper Jaffray Health Care Conference on December 1 in New York City.
-
Nov 19, 2010Innovative percutaneous aortic valve replacement system provides entry into emerging market of structural heart disease
Boston Scientific Corporation (NYSE: BSX) today announced the signing of a definitive merger agreement, under which...
-
Nov 19, 2010
Boston Scientific Corporation (NYSE: BSX) today announced CE Mark approval of its INCEPTA™, ENERGEN™ and PUNCTUA™ cardiac resynchronization...
-
Nov 17, 2010
Boston Scientific Corporation (NYSE: BSX) today announced that its newly acquired subsidiary, Asthmatx, Inc., was awarded the 2010 Popular Science...
-
Nov 11, 2010Company supports efforts of International Diabetes Federation to promote worldwide diabetes education and prevention
Boston Scientific Corporation (NYSE: BSX) today announced its sponsorship of "World Diabetes Day" for the third year in a row. The campaign is led by the...
-
Nov 10, 2010
Boston Scientific Corporation (NYSE: BSX) today announced that it will be hosting an Investor Day meeting, which will be simultaneously...
-
Nov 9, 2010Company implants its first Deep Brain Stimulation device designed to treat Parkinson's
Boston Scientific Corporation (NYSE: BSX) today announced the first implantation of its Vercise™ Deep Brain Stimulation (DBS) System as part...
-
Nov 2, 2010Two-year data presented at CHEST 2010 demonstrate ability of FDA-approved, non-drug asthma treatment to provide long-lasting symptom control
Boston Scientific Corporation (NYSE: BSX) today announced that its newly acquired subsidiary, Asthmatx, Inc., presented two-year...
-
Oct 28, 2010
Boston Scientific Corporation (NYSE: BSX) today announced the execution of a definitive agreement under which Stryker Corporation will acquire...
-
Oct 26, 2010
Boston Scientific Corporation (NYSE: BSX) today announced the completion of its acquisition of Asthmatx, Inc. of Sunnyvale, California. The...
-
Oct 22, 2010Company's fully covered metal stent now approved for use in treating benign biliary strictures
Boston Scientific Corporation (NYSE: BSX) today announced that its WallFlex® Biliary RX Fully Covered Stent has received CE Mark approval for the treatment...
-
Oct 21, 2010Latest innovation in plastic biliary stent technology includes features for enhanced deliverability, efficiency and procedural control
Boston Scientific Corporation (NYSE: BSX) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration and CE...
-
Oct 19, 2010
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the third quarter ended September 30, 2010, as well as guidance for...
-
Oct 13, 2010Major advance in guidewire technology for challenging peripheral interventions
Boston Scientific Corporation (NYSE: BSX) today announced the global launch of its Journey™ Guidewire, an innovative 0.014" guidewire designed for use in...
-
Oct 7, 2010
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the third quarter ended September 30,...
-
Sep 28, 2010MADIT II eight-year outcomes analysis shows that one life is saved for every eight patients who receive an ICD
Boston Scientific Corporation (NYSE: BSX) today welcomed the publication of an analysis of long-term data from the MADIT II clinical trial in the...
-
Sep 25, 2010
Boston Scientific Corporation (NYSE: BSX) today announced three-year follow-up data from the HORIZONS-AMI trial. The trial, sponsored by the...
-
Sep 22, 2010Company presents one-year clinical data at TCT on its platinum chromium paclitaxel-eluting coronary stent from PERSEUS trial
Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of 1,166 patients from its PERSEUS clinical program comparing...
-
Sep 22, 2010Results of TAXUS ATLAS clinical program presented at TCT
Boston Scientific Corporation (NYSE: BSX) today announced comprehensive data from the TAXUS ATLAS clinical program, a series of global,...
-
Sep 21, 2010Nine-month results from PLATINUM clinical program presented at TCT
Boston Scientific Corporation (NYSE: BSX) today announced data from its PLATINUM QCA study, which is designed to evaluate the Company's PROMUS Element™...
-
Sep 21, 2010
Boston Scientific Corporation (NYSE: BSX) today announced that its PROMUS® Element™ Everolimus-Eluting Coronary Stent System has received CE...
-
Sep 20, 2010Asthmatx offers first FDA-approved non-drug procedure for the treatment of severe asthma
Boston Scientific Corporation (NYSE: BSX) today announced the signing of a definitive merger agreement, under which Boston...
-
Sep 16, 2010FDA approval is based on results from the Company's landmark MADIT-CRT trial
Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for...
-
Sep 14, 2010Company to present clinical data on its platinum chromium PROMUS® Element™ and TAXUS® Element™ Coronary Stent Systems
Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the Cardiovascular Research...
-
Sep 2, 2010
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Morgan Stanley Global Healthcare Conference on September 14th in New...
-
Aug 19, 2010
Boston Scientific Corporation (NYSE: BSX) today announced that results from studies involving the Company's Women's Health products will be...
-
Aug 11, 2010
Boston Scientific Corporation (NYSE: BSX) today announced that it has been notified by the U.S. Food and Drug Administration that all issues cited...
-
Aug 3, 2010EVOLVE trial to evaluate Company's fourth-generation SYNERGY™ drug-eluting coronary stent
Boston Scientific Corporation (NYSE: BSX) today announced the start of patient enrollment in the EVOLVE clinical trial, which is designed to assess...
-
Jul 29, 2010Company now offers pain specialists the most comprehensive portfolio of SCS percutaneous leads
Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration approval of two spinal cord stimulation (SCS) leads for...
-
Jul 29, 2010
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the BMO Capital Markets Healthcare Conference on August 5th in New York....
-
Jul 26, 2010Company expands market-leading family of neurovascular stents
Boston Scientific Corporation (NYSE: BSX) today announced the U.S. and European launches of the Neuroform EZ™ Stent System, its fourth-generation...
-
Jul 20, 2010
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the second quarter ended June 30, 2010, as well as guidance for net...
-
Jul 8, 2010
Boston Scientific Corporation (NYSE: BSX) today announced enrollment of the first patient in its MultiSENSE clinical trial. The trial is designed to...
-
Jul 7, 2010
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the second quarter ended June 30, 2010...
-
Jun 24, 2010Two new splitters allow multi-site placement of up to four spinal cord stimulation leads
Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration approval and launch of two spinal cord stimulation...
-
Jun 23, 2010
Boston Scientific Corporation (NYSE: BSX) today announced the successful syndication of a new $1 billion, three-year term loan and a new $2...
-
Jun 21, 2010Longer balloons provide physicians more options for treating peripheral artery disease
Boston Scientific Corporation (NYSE: BSX) today announced that 22 new balloon sizes have been added to the PolarCath® Peripheral Dilatation...
-
Jun 18, 2010
Boston Scientific Corporation (NYSE: BSX) today announced results from a sub-analysis of the MADIT-CRT trial data that showed...
-
Jun 14, 2010
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Wells Fargo Healthcare Conference on June 24th in Boston. Ray Elliott,...
-
Jun 11, 2010
Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's key events and sponsored research at the 17th Cardiostim...
-
Jun 10, 2010CE Mark approval includes specific indication for treatment of diabetic patients
Boston Scientific Corporation (NYSE: BSX) today announced the market launch and first implants of its TAXUS® Element™ Paclitaxel-Eluting...
-
Jun 2, 2010
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Goldman Sachs 31st Annual Global Healthcare Conference on June 16th in...
-
May 26, 2010Randomized study of nearly 3,000 patients to evaluate Company's third-generation drug-eluting stent technology
Boston Scientific Corporation (NYSE: BSX) today announced the initiation of the PLATINUM PLUS clinical trial, an investigator-sponsored research...
-
May 25, 2010
Boston Scientific Corporation (NYSE: BSX) today announced CE Mark and U.S. Food and Drug Administration (FDA) approval of its NC Quantum Apex™...
-
May 24, 2010Company's iLab® Ultrasound Imaging System compatible with leading X-ray systems
Boston Scientific Corporation (NYSE: BSX) today announced collaborations with Philips Healthcare and Siemens Medical Solutions to enable the use of...
-
May 20, 2010
Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events at the annual EuroPCR Scientific Program, May...
-
May 19, 2010Company expands Sterling line of peripheral angioplasty balloon catheters to include long balloons designed for below-the-knee procedures
Boston Scientific Corporation (NYSE: BSX) today announced the U.S. and European launches of the Sterling® SL PTA Balloon Dilatation Catheter, a...
-
May 18, 2010Next-generation system strengthens Company's endometrial ablation portfolio for the treatment of menorrhagia
Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval of its Genesys HTA™ System for the...
-
May 13, 2010
Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration clearance of the ACUITY Break-Away™ Lead Delivery...
-
May 12, 2010Approval includes specific indication for treatment of diabetic patients
Boston Scientific Corporation (NYSE: BSX) today announced it has received CE Mark approval for its TAXUS® Element™ Paclitaxel-Eluting Coronary...
-
May 11, 2010
Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval for LATITUDE 6.0, a software upgrade to...
-
May 10, 2010
Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and sponsored research at the 31st Annual...
-
May 4, 2010Results of study using Boston Scientific's WallFlex® Duodenal Stent presented at Digestive Disease Week®
Boston Scientific Corporation (NYSE: BSX) today announced results from a study demonstrating that endoscopic duodenal stenting is...
-
May 3, 2010EVIDENCE Trial to study Boston Scientific's Precision Plus™ Spinal Cord Stimulator System
Boston Scientific Corporation (NYSE: BSX) today announced the start of patient enrollment in the EVIDENCE Clinical Trial, which compares the...
-
Apr 30, 2010Positive results to be presented for SpyGlass® Direct Visualization System, Radial Jaw® 4 Biopsy Forceps and WallFlex® Duodenal Stents
Boston Scientific Corporation (NYSE: BSX) today announced that multiple clinical abstracts examining the diagnostic and therapeutic utility of its...
-
Apr 29, 2010Educational forum includes lab training sessions and online community for urogynecologists, urologists and surgical gynecologists
Boston Scientific Corporation (NYSE: BSX) today announced the launch of the Pelvic Floor Institute™ -- a unique training forum and online...
-
Apr 27, 2010
Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. District Court in Minnesota declined to accept the plea agreement between...
-
Apr 26, 2010Company records $1.8 billion goodwill impairment charge
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the first quarter ended March 31, 2010, as well as guidance for...
-
Apr 22, 2010Major advance in guidewire technology provides exceptional torque and flexibility for coronary procedures
Boston Scientific Corporation (NYSE: BSX) today announced the launch of its new Kinetix™ Guidewire for use in percutaneous coronary intervention...
-
Apr 21, 2010
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the upcoming Bank of America Merrill Lynch Health Care Conference in New...
-
Apr 19, 2010
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the upcoming Deutsche Bank Health Care Conference in Boston on May 4. Ray...
-
Apr 19, 2010Exclusive agreement promotes access to testing solutions for female urinary incontinence
Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a four-year exclusive marketing agreement with Bladder Health...
-
Apr 15, 2010Boston Scientific to Immediately Resume Distribution of COGNIS® CRT-Ds and TELIGEN® ICDs in the U.S.
Boston Scientific Corporation (NYSE: BSX) today announced that it has received U.S. Food and Drug Administration (FDA) clearance for the two...
-
Apr 15, 2010
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2010...
-
Mar 18, 2010Company's CRT-Ds recommended for asymptomatic and mild heart failure patients
Boston Scientific Corporation (NYSE: BSX) today announced that the Circulatory System Devices Panel of the U.S. Food and Drug Administration (FDA)...
-
Mar 16, 2010Trials to evaluate small vessel and long lesion versions of platinum chromium PROMUS® Element™ Stent System
Boston Scientific Corporation (NYSE: BSX) today announced the completion of patient enrollment in the Small Vessel and Long Lesion trials of its...
-
Mar 15, 2010Boston Scientific applies to FDA for expanded indications for TAXUS Express and TAXUS® Liberte® Stents in AMI patients
Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of one-year subset data from the HORIZONS AMI trial...
-
Mar 15, 2010
Boston Scientific Corporation (NYSE: BSX) today announced 12-month results from its PERSEUS clinical program that demonstrated...
-
Mar 15, 2010
Boston Scientific Corporation (NYSE: BSX) announced today that it has stopped shipment and is retrieving field inventory of all its implantable...
-
Mar 11, 2010First and only premounted, balloon-expandable stent approved specifically for use in iliac arteries
Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved its Express® LD Iliac...
-
Mar 10, 2010Clinical data presentations to include 12-month results for third-generation TAXUS® Element™ drug-eluting stent
Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and news announcements at the 59th Annual...
-
Feb 23, 2010
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the upcoming RBC Capital Markets Health Care Conference in New York City....
-
Feb 10, 2010
Boston Scientific Corporation (NYSE: BSX) today rebutted an article published in the journal HeartRhythm. The article reported a case summary of...
-
Feb 10, 2010New structure, leadership team and targeted portfolio changes will focus on sales excellence and cost effectiveness
Boston Scientific Corporation (NYSE: BSX) today announced a series of management changes and restructuring initiatives designed to strengthen the...
-
Feb 10, 2010
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the fourth quarter and full year ended December 31, 2009, as well...
-
Feb 1, 2010
Boston Scientific Corporation (NYSE: BSX) today announced the settlement of three patent disputes with Johnson & Johnson (J&J). The disputes date...
-
Jan 20, 2010
Boston Scientific Corporation (NYSE: BSX) announced today that the U.S. District Court for the District of Delaware has found all four patents in a...
-
Jan 19, 2010
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the fourth quarter and the year ended...
-
Jan 14, 2010
Boston Scientific Corporation (NYSE: BSX) today announced that the first patient has been enrolled in a clinical trial to...
-
Jan 8, 2010Boston Scientific only company to offer choice of two distinct drugs on separate drug-eluting stent platforms
Boston Scientific Corporation (NYSE: BSX) announced today that it has received approval from the Japanese Ministry of Health, Labor and Welfare...
-
Jan 5, 2010
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the upcoming J.P. Morgan Health Care Conference in San Francisco. Ray...
-
Jan 5, 2010
Boston Scientific Corporation (NYSE: BSX) today announced that it has completed enrollment in its MAPS™ clinical trial, which is studying the...
-
Jan 4, 2010Company to contribute data to industry-sponsored Dual Antiplatelet Therapy (DAPT) Study
Boston Scientific Corporation (NYSE: BSX) today announced that it has enrolled the first patient in its TAXUS Liberte post-approval study. The study...
-
Dec 23, 2009
Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a civil settlement with the U.S. Department of Justice regarding...
-
Dec 16, 2009
Boston Scientific Corporation (NYSE: BSX) today announced that the Company's Board of Directors has elected Nelda Connors as a Director. Ms....
-
Dec 14, 2009
Boston Scientific Corporation (NYSE: BSX) today announced the completion of a public offering of $2 billion aggregate principal amount of its...
-
Dec 10, 2009
Boston Scientific Corporation (NYSE: BSX) today announced the pricing of a public offering of $2 billion aggregate principal amount of its senior...
-
Nov 23, 2009
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Piper Jaffray Health Care Conference, December 1-2. Ray Elliott,...
-
Nov 20, 2009Complete portfolio of Company's WallFlex Stent family of self-expanding metal stents now available in U.S., Europe and other international markets
Boston Scientific Corporation (NYSE: BSX) today announced that it has received 510(k) clearance from the U.S. Food and Drug...
-
Nov 10, 2009Company supports efforts of International Diabetes Federation to promote worldwide diabetes education and prevention
Boston Scientific Corporation (NYSE: BSX) today announced its official sponsorship of "World Diabetes Day" for the second year in a row. The...
-
Nov 9, 2009
Boston Scientific Corporation (NYSE: BSX) today announced its schedule of events at the 38th annual Global Congress for Minimally Invasive...
-
Nov 9, 2009COGNIS® CRT-D and TELIGEN® ICD are the world's smallest and thinnest high-energy devices
Boston Scientific Corporation (NYSE: BSX) today announced the launch of its COGNIS® cardiac resynchronization therapy defibrillator (CRT-D) and...
-
Nov 6, 2009Company updates third quarter financial results and full-year 2009 guidance
Boston Scientific Corporation (NYSE: BSX) today announced that it has reached an agreement in principle with the U.S. Department of Justice (DOJ)...
-
Nov 2, 2009Third-generation drug-eluting stent now available in CE Mark countries
Boston Scientific Corporation (NYSE: BSX) today announced it has received CE Mark for its PROMUS® Element™ Everolimus-Eluting Coronary Stent...
-
Oct 19, 2009
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the third quarter ended September 30, 2009, as well as guidance for...
-
Oct 9, 2009
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the third quarter ended September 30,...
-
Oct 6, 2009Three models of stenting system now available for palliative treatment of malignant common bile duct strictures
Boston Scientific Corporation (NYSE: BSX) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to...
-
Oct 5, 2009
Boston Scientific Corporation (NYSE: BSX) today announced its exclusive sponsorship and first enrollments of the MADIT-RIT clinical trial. This new...
-
Sep 29, 2009
Boston Scientific Corporation (NYSE: BSX) today announced the settlement of more than a dozen lawsuits involving Johnson & Johnson, including the...